<DOC>
	<DOCNO>NCT02340234</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study evaluate safety efficacy lebrikizumab administer subcutaneously ( SC ) adult participant persistent moderate severe atopic dermatitis ( AD ) inadequately control topical corticosteroid ( TCS ) . The study include screen visit , 2-week run-in period , 12-week blind treatment period , 8-week safety follow-up period . Following screen visit , eligible participant enter run-in period ( Days − 14 − 1 ) protocol-specified topical therapy regimen initiate . At end run-in period , participant : 1 ) demonstrate compliance protocol-specified TCS regimen , 2 ) continue fulfill eligibility criterion randomize .</brief_summary>
	<brief_title>A Study Lebrikizumab Participants With Persistent Moderate Severe Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>AD diagnose Hanifin/Rajka criterion present least 1 year screen Moderate severe AD grade Rajka/Langeland criterion screen History inadequate response &gt; /= 1 month ( within 3 month prior screen visit ) treatment regimen least daily TCS regular emollient treatment AD EASI score &gt; /= 14 screen end runin period IGA score &gt; /= 3 ( 5point scale ) screen end runin period AD involvement &gt; /= 10 % BSA screening Pruritus VAS score &gt; /= 3 screening Past and/or current use antiinterleukin ( IL ) 13 antiIL4/IL13 therapy , include lebrikizumab Use investigational agent within 4 week prior screen within 5 halflives investigational agent , whichever long History severe allergic reaction anaphylactic reaction biologic agent know hypersensitivity component lebrikizumab injection Use complementary , alternative , homeopathic medicine include , limited , phytotherapy , traditional nontraditional herbal medication , essential fatty acid , acupuncture within 7 day prior runin period need medication study Evidence skin condition ; include , limited , Tcell lymphoma allergic contact dermatitis Evidence , ongoing treatment ( include topical antibiotic ) active skin infection screen Other recent infection meet protocol criterion Active tuberculosis require treatment within 12 month prior Visit 1 Evidence acute chronic hepatitis know liver cirrhosis Known immunodeficiency , include human immunodeficiency virus ( HIV ) infection Use topical calcineurin inhibitor ( TCI ) time screen , unless participant willing stop TCI use study ( include runin period ) , investigator 's opinion , safe Clinically significant abnormality screen electrocardiogram ( ECG ) laboratory test , opinion investigator , may pose additional risk administer study drug TCS participant Known current malignancy current evaluation potential malignancy , include basal squamous cell carcinoma skin carcinoma situ History malignancy within 5 year prior screen , except appropriately treat carcinoma situ cervix , nonmelanoma skin carcinoma , Stage I uterine cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>